Mirum Pharmaceuticals (MIRM) SVP Jolanda Howe receives options, RSUs and PSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Mirum Pharmaceuticals senior vice president and global controller Jolanda Howe reported new equity awards in the company. On January 28, 2026, she received stock options for 7,680 shares of common stock with an exercise price of $100.85 per share, vesting over four years starting one year after that date.

She was also granted 4,970 restricted stock units, each representing one share of common stock. These RSUs vest in three equal annual installments on each anniversary of January 28, 2026. In addition, 9,000 performance restricted stock units previously granted on January 23, 2024 were confirmed to have met their performance criteria, and will vest two-thirds on March 15, 2026 and one-third on March 15, 2027.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Howe Jolanda

Role SVP, GLOBAL CONTROLLER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,680	$0.00	--
Grant/Award	Restricted Stock Units	4,970	$0.00	--
Grant/Award	Performance Restricted Stock Units	9,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 7,680 shares (Direct); Restricted Stock Units — 4,970 shares (Direct); Performance Restricted Stock Units — 9,000 shares (Direct)

Footnotes (1)

1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

Form 4 Insider Transactions: What Each Field Means →

01/30/2026 - 06:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GLOBAL CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$100.85	01/28/2026		A		7,680		⁽¹⁾	01/27/2036	Common Stock	7,680	$0	7,680	D
Restricted Stock Units	⁽²⁾	01/28/2026		A		4,970		⁽³⁾	⁽³⁾	Common Stock	4,970	$0	4,970	D
Performance Restricted Stock Units	⁽²⁾	01/28/2026		A		9,000		⁽⁴⁾	⁽⁴⁾	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

4. On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mirum Pharmaceuticals (MIRM) report for Jolanda Howe?

Mirum Pharmaceuticals reported that SVP and global controller Jolanda Howe received new equity awards on January 28, 2026. These included stock options, restricted stock units, and performance-based restricted stock units, all granted as part of her compensation and held as direct beneficial ownership.

How many stock options did Jolanda Howe receive from Mirum Pharmaceuticals (MIRM)?

Jolanda Howe received stock options covering 7,680 shares of Mirum Pharmaceuticals common stock. The options have an exercise price of $100.85 per share and vest over four years, beginning one year after January 28, 2026, with the remaining options vesting in 36 equal monthly installments.

What are the terms of Jolanda Howe’s restricted stock units at Mirum Pharmaceuticals (MIRM)?

She was granted 4,970 restricted stock units, each representing one share of common stock. One-third of these RSUs vest on each anniversary of January 28, 2026, so the entire award will be fully vested on the three-year anniversary of that vesting commencement date.

What performance restricted stock units did Jolanda Howe hold at Mirum Pharmaceuticals (MIRM)?

Jolanda Howe holds 9,000 performance restricted stock units granted on January 23, 2024. Performance criteria were determined to be met on January 28, 2026. Two-thirds of these PSUs vest on March 15, 2026, and the remaining one-third vest on March 15, 2027.

Is Jolanda Howe’s ownership in Mirum Pharmaceuticals (MIRM) direct or indirect?

The Form 4 indicates that Jolanda Howe’s reported holdings are directly owned. The stock options, restricted stock units, and performance restricted stock units are all listed with a direct ownership form, with no separate entity or indirect beneficial ownership structure described.

What role does Jolanda Howe hold at Mirum Pharmaceuticals (MIRM)?

Jolanda Howe is an officer of Mirum Pharmaceuticals, serving as senior vice president and global controller. The equity awards reported on the Form 4 appear to be part of her executive compensation, aligning her interests with the company’s long-term performance.